Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

Septerna Inc. SEPN and Novo Nordisk A/S NVO announced an exclusive global collaboration and license agreement on Wednesday. The pact covers discovering, developing, and commercializing oral small ...

Novo Nordisk on Wednesday said it will collaborate with biotechnology startup Septerna to hunt new obesity drug prospects, agreeing to pay the California drugmaker more than $200 million in ...

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...